-
2025-524322-18-00
5
Non-active Secondary Progressive Multiple Sclerosis (SPMS)
-
2025-524337-11-00
5
Systemic Sclerosis
-
2025-524487-37-00
6
Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MP
-
2025-524646-94-00
11
Obstetrics – Preeclampsia
-
2025-520565-51-00
5
2026-06-23
small cell lung cancer
-
2025-523579-47-00
4
2026-06-19
moderate to severe rheumatoid arthritis (RA)
-
2025-524843-11-00
4
2026-06-15
Non-Small Cell Lung Cancer
-
2025-523443-35-00
5
2026-06-11
Persistent Corneal Epithelial Defect (PCED)
-
2025-524316-11-00
5
2026-06-11
Primary Progressive Multiple Sclerosis (PPMS)
-
2025-524056-63-00
1
2026-06-05
microsatellite instability high/mismatch repair deficient (MSI-H/dMMR)
-
2025-524038-24-00
5
2026-05-22
Focal Epilepsy
-
2024-519870-38-00
5
2026-05-11
Atherosclerotic cardiovascular disease (ASCVD)
-
2023-508047-40-00
5
2026-04-30
Ovarian cancer
-
2024-519818-31-01
5
2026-04-10
Endometrial Cancer
Advanced, Recurrent, Metastatic, or Primary Unresec
-
2025-521521-33-00
10
2026-04-02
Kidney transplant rejection
-
2024-513911-28-00
10
2026-03-04
Acute Ischemic Stroke
-
2025-522553-19-00
10
2026-02-25
Symptomatic genetic and familial dilated cardiomyopathy.
-
2024-520027-88-00
4
2026-02-12
Patients with hormone receptor-positive (HR+) breast cancer
-
2023-508995-12-01
4
2025-12-24
Recurrent or metastatic non-small cell lung cancer (NSCLC)
-
2024-510778-26-00
4
2025-12-19
Metastatic Non-Small-Cell Lung Cancer
-
2024-518899-31-00
5
2025-12-19
Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy
-
2024-519901-36-00
5
2025-12-17
Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC
-
2024-512029-10-00
5
2025-12-05
Intermediate risk, non-muscle invasive bladder cancer
-
2025-521034-28-00
4
2025-12-05
Moderate to Severe Rheumatoid Arthritis (RA)